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Increased serum CA 19-9 levels in patients with nonmalignant diseases have been inves-
tigated in previous reports. This study evaluates the clinical signiﬁcance of serum CA 19-9
elevation in pulmonary nontuberculous mycobacterial disease and pulmonary tuberculosis.
The  median CA 19-9 level was higher in patients with pulmonary nontuberculous mycobac-
terial  disease than in patients with pulmonary tuberculosis (pulmonary nontuberculous
mycobacterial disease: 13.80, tuberculosis: 5.85, p < 0.001). A multivariate logistic regres-
sion  analysis performed in this study showed that Mycobacterium abscessus (OR 9.97, 95%
CI:  1.58, 62.80; p = 0.014) and active phase of pulmonary nontuberculous mycobacterial dis-
ease  (OR 12.18, 95% CI: 1.07, 138.36, p = 0.044) were found to be risk factors for serum CA 19-9
elevation in pulmonary nontuberculous mycobacterial disease. The serum CA 19-9 levels
showed a tendency to decrease during successful treatment of pulmonary nontuberculous
mycobacterial disease but not in pulmonary tuberculosis. These ﬁndings suggest that CA19-9  may be a useful marker for monitoring therapeutic responses in pulmonary nontuber-
culous mycobacterial disease, although it is not pulmonary nontuberculous mycobacterial
disease-speciﬁc marker.Introduction
Pulmonary nontuberculous mycobacterial (PNTM) disease
appears to be increasing in many  regions of the world, and
1–4the burden of PNTM is substantial. In South Korea and
other regions in which the incidence of tuberculosis (TB) is
intermediate, differential diagnosis between PNTM and TB has
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become an important issue as nontuberculous mycobacteria
(NTM) isolation from respiratory specimens has increased.5,6
In PNTM disease, there is a lack of known biomarkers
associated with disease activity and therapeutic response.
Diagnosis of PNTM disease is deﬁned by clinical criteria,nal Medicine, Yonsei University College of Medicine, 50-1 Yonseiro,
radiographic presentation, and microbiologic results. Addi-
tionally, the goal of the treatment of PNTM disease includes
symptomatic, radiographic, and microbiologic improvement.
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owever, sputum specimen is frequently not achievable in
ome patients; the symptom proﬁle of PNTM disease varies,
nd subjective assessment of the clinician has often come
nto play. Thus, many  clinicians rely on radiography includ-
ng chest X-ray and high-resolution computed tomography
CT) scanning to assess the severity of PNTM disease7 and for
he monitoring of the treatment response. However, repeat-
ng CT scans increases cost and cumulative radiation dose.
hus, there is a need to identify biomarkers to estimate PNTM
isease severity and to monitor treatment response.
Carbohydrate antigen 19-9 (CA 19-9) is a sialylated Lewis
Le) blood group antigen and a widely used tumor marker
or epithelial type gastrointestinal cancers, especially pancre-
tic cancer.8,9 However, elevated levels of CA 19-9 can also
e detected in patients with nonmalignant diseases includ-
ng pancreatic, liver, and biliary diseases.10–12 In particular,
here are several reports of increased serum CA 19-9 in sev-
ral benign lung diseases including diffuse panbronchiolitis,
mphysema, ﬁbrosis, and bronchiectasis.12–14
A previous study reported that increased serum CA 19-9
evels may indicate clinical deterioration of PNTM disease15
nd some reports suggest that elevated CA 19-9 levels
ecreased after successful treatment of PNTM disease, con-
rary to pulmonary tuberculosis.16–18
The aim of this study was to investigate the clinical sig-
iﬁcance of serum CA 19-9 elevation in PNTM diseases. We
valuated the factors associated with CA 19-9 elevation in
NTM disease and compared the change of CA 19-9 levels as
 result of treatment of patients with either PNTM disease or
B patients.
aterials  and  methods
atients  and  data  collection
 total of 59 patients with PNTM disease and 36 patients with
ulmonary TB who  visited Severance Hospital, a university-
fﬁliated tertiary referral hospital in South Korea, between
arch 2011 and December 2013 were enrolled. All patients
rovided written informed consent before enrollment and this
rospective study was approved by the Ethics Review Com-
ittee of Severance Hospital. Any patients with active cancer
ithin ﬁve years based on medical chart review and interview
ere excluded.
PNTM disease was diagnosed based on the American
horacic Society (ATS) guidelines.19 Radiologic disease types
f PNTM were categorized as nodular bronchiectatic (NB),
brocavitary (FC), or mixed. Although the NB form was
haracterized with bronchiectasis and multiple centrilobular
odules, the FC form was deﬁned as a ﬁbrocavitary lesion
n chest CT. The number of involved lobes was investigated
s an indicator of radiological severity. NTM species were
dentiﬁed via a polymerase chain reaction (PCR)-restriction
ragment length polymorphism method based on the rpoB
ene.6,20 Among 59 patients with PNTM disease, 24 patients
ere treated with anti-NTM regimens according to the ATS
uidelines.19 Active phase of PNTM disease was deﬁned as
resent in patients with persisting positive microbiological
ultures and clinical deterioration based on symptoms and 1 6;2  0(1):26–32 27
radiographic ﬁndings, who was treated for PNTM disease or
was advised to treat in six month.
Twenty-two patients with MAC (Mycobacterium avium-
intracellulare) lung disease received a standardized antibiotic
combination consisting of clarithromycin (1000 mg/day),
rifampicin (450 mg for patients who were <50 kg or 600 mg  for
patients who were ≥50 kg), and ethambutol (25 mg/kg for two
months, then 15 mg/kg/day).19 Two patients with M.  abscessus
complex lung disease were treated with a standardized reg-
imen consisting of intravenous cefoxitin (12 g/day), amikacin
(10–15 mg/kg) and azithromycin (250 mg/day).19 The treatment
duration was usually 24 months including at least 12 months
after sputum culture conversion.21
Response to anti-NTM treatment was deﬁned as sputum
culture conversion and radiographic improvement within 12
months of treatment. Culture conversion was deﬁned as three
consecutive negative sputum cultures from the date of the ﬁrst
negative culture after the start of anti-NTM treatment.21
The diagnosis of active pulmonary TB was based on posi-
tive respiratory specimen culture or the presence of caseating
granulomas in lung tissue. Additionally, patients with nega-
tive mycobacterial culture but with high likelihood of active
TB and overall good responses after TB treatment were
included. TB patients who were lost to follow-up during anti-
TB treatment period or had concomitant immunosuppressive
diseases requiring therapy or clinical conditions (such as HIV
infection, lymphoma) were excluded. Patients were classiﬁed
as low or moderate/high risk according to the risk factors for
relapse. The risk factors for relapse were as follows: (1) cav-
itary lesion on chest imaging at diagnosis and (2) positive
sputum culture after two months of anti-TB treatment.22 The
risk groups were classiﬁed according to the number of risk fac-
tors for relapse: two risk factors in the high risk group; one risk
factor in the moderate risk group; and no risk factor in low risk
group.
Measurement  of  serum  CA  19-9
Blood samples were separated via centrifugation and frozen
immediately at −70 ◦C. Serum CA 19-9 levels were measured
with an Analytics E 170 (Elecsys module) immunoassay ana-
lyzer (Roche Diagnostics GmbH, Mannheim, Germany) using
the electrochemiluminescence immunoassay technique. The
normal range was deﬁned as <34 U/mL according to the man-
ufacturer’s instructions.
Serum C-reactive protein (CRP) was measured via Chem-
istry Autoanalyzer Hitachi 7600 (Hitachi Co., Japan) with
Daiichi reagent (Daiichi-Hitachi) using the turbidoimmuno-
metric assays (TIA) technique with the normal range deﬁned
as <0.30 mg/dL according to the manufacturer’s instructions.
Serum CA 19-9 was measured before treatment in all patients
and also measured again after at least 12 months of treatment
in 24 patients with PNTM disease and after the completion of
treatment in all TB patients.
Statistical  analysisCategorical variables were analyzed using the 2 test and
continuous variables were analyzed using the Mann–Whitney
test. The non-parametric Wilcoxon signed-rank test was used
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Fig. 1 – Serum CA 19-9 in patients with pulmonary
nontuberculous mycobacterial (PNTM) disease and active
tuberculosis (TB). PNTM disease, pulmonary28  b r a z j i n f e c t d
for comparisons before and after treatment. Multivariate
logistic regression analysis was performed to evaluate the
factors related to CA 19-9 elevation. Variables with p < 0.1 in
the univariate analysis were entered into a multiple logis-
tic regression model. All data were analyzed using GraphPad
Prism 5.0 (GraphPad, San Diego, CA, USA) and SPSS v. 20.0
(SPSS Inc., Chicago, IL, USA). A p-value <0.05 was considered
to indicate signiﬁcance.
Results
Comparisons  between  patients  with  PNTM  disease  and
patients  with  pulmonary  TB
The baseline clinical characteristics of the patients are pre-
sented in Table 1. The proportion of female patients was higher
among patients with PNTM disease than in patients with pul-
monary TB. The median age of the patients with PNTM disease
was higher than in patients with pulmonary TB (PNTM: 63,
TB: 26.5, p < 0.001). Radiologic severity deﬁned by extension
into more  than three lobes was more  frequent in patients with
PNTM disease, but cavitary lesions were similar between the
two groups. The proportion of subjects with AFB positivity and
previous TB history was higher in patients with PNTM disease
than in patients with pulmonary TB.
The median CA 19-9 level was higher in patients with PNTM
disease than in patients with pulmonary TB (PNTM: 13.80, TB:
5.85, p < 0.001, Fig. 1).
Comparisons  between  patients  with  normal  and  elevated
CA 19-9  levels  in  PNTM  diseaseThe CA 19-9 levels of 59 patients with PNTM disease were mea-
sured before NTM treatment; these patients were divided into
two groups: ‘Normal CA 19-9 levels’ and ‘Elevated CA 19-9 lev-
els’ (Table 2). The subjects with ‘Elevated CA 19-9 levels’ were
Table 1 – Clinical characteristics of patients with pulmonary no
tuberculosis (TB).
PNTM disease
(n = 59)
Sex, female 45 (76.3%) 
Agea 63 (43, 84) 
BMIb 20 (18.0, 22.0) 
Smoking presence 
Never 49 (83.1%) 
Ever 10 (16.9%) 
Past TB 21 (35.6%) 
AFB smear positive 12 (20.3%) 
Extension more than three lobes 28 (47.5%) 
Cavity 21 (35.6%) 
2-Month culture (+) after TB treatment – 
Extrapulmonary TB – 
Drug resistant TB – 
PNTM disease: pulmonary nontuberculous mycobacterial disease, TB: tub
a Presented as median (ranges).
b Presented as medians (IQR).nontuberculous mycobacterial disease.
all females. Body mass index (BMI), radiologic disease type,
and serum CRP levels did not differ between the two  groups.
Through univariate analysis, extensive pulmonary lesions
involving more  than three lobes (p = 0.021), M.  abscessus
(p = 0.002), previous TB history (p = 0.028), and active phase of
PNTM disease (p = 0.010) were associated with elevated CA 19-9
levels (Table 3). In a subsequent multivariate logistic analysis,
Mycobacterium abscessus (OR 9.97, 95% CI: 1.58, 62.80; p = 0.014)
and active phase of PNTM disease (OR 12.18, 95% CI: 1.07,
138.36, p = 0.044) were associated with an elevated CA 19-9
levels (Table 3).
Changes  of  CA  19-9  levels  following  treatmentSerial CA 19-9 measurements were obtained in 24 patients
with PNTM disease and 36 patients with pulmonary TB (Fig. 2).
ntuberculous mycobacterial (PNTM) disease and active
TB
(n  = 36)
p-Value
18 (50%) 0.009
26.5 (22, 69) <0.001
19.72 (18.8, 21.9) 0.664
0.066
24 (66.7%)
12 (33.3%)
1 (2.8%) <0.001
3 (8.3%) 0.153
3 (8.3%) <0.001
11 (30.6%) 0.614
1 (2.8)
3 (8.4)
3 (8.4)
erculosis, BMI: body mass index, AFB: acid fast bacilli.
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Table 2 – Characteristics of patients with pulmonary nontuberculous mycobacterial (PNTM) disease according to the CA
19-9 level.
Normal CA 19-9
(n = 48)
Elevated CA 19-9
(n = 11)
p-Value
Sex, female 34 (70.8%) 11 (100%) 0.036
Agea 64 (43, 84) 60 (46, 76) 0.067
BMIb 20.1 (18.6, 22.3) 19.9 (17.9, 23.5) 0.977
Smoking
Never 38 (79.2%) 11 (100%) 0.252
Ex-smoker 8 (16.7%) 0 (0%)
Current 2 (4.2%) 0 (0%)
Past TB history 13 (27.1%) 7 (63.6%) 0.027
AFB smear positivity 10 (20.8%) 2 (18.2%) 0.606
Brochiectasis 45 (93.8%) 9 (81.8%) 0.23
Radiologic disease type
Nodularbronchiectatic (NB) 30 (62.5%) 8 (72.7%) 0.76
Fibrocavity (FC) 1 (2.1%) 0 (0.0%)
NB + FC form 17 (35.4%) 3 (27.3%)
Radiologic severity
>3 lobes 19 (39.6%) 9 (81.8%) 0.013
≤3 lobes 29 (60.4%) 2 (18.2%)
Main species 0.007
MAC 37  (77.1%) 3 (27.3%)
M. abscessus complex 4 (8.3%) 2 (18.2%)
MAC + M. abscessus complex 6 (12.5%) 6 (54.5%)
M. kansasii 1 (2.1%) 0 (0%)
PNTM disease treatment 16 (33.3%) 8 (72.7%) 0.037
Active phase of PNTM disease 18 (37.5%) 10 (90.9%) 0.002
Sputum culture conversionc 9 (37.5%) 3 (37.5%) >0.95
CRP (mg/dL)b 0.11 (0.06, 0.33) 0.1 (0.06, 0.19) 0.633
MAC: Mycobacterium avium-intracellulare,  BMI: body mass index, TB: tuberculosis, AFB: acid fast bacilli.
a Are presented as median (Ranges).
b Are presented as medians (IQR).
c Data are numbers (percentages) of patients with PNTM disease who received NTM treatment.
M. abscessus complex includes M. abscessus and M. massiliense.
Table 3 – Factors associated with elevated CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial
(PNTM) disease.
CA 19-9 ≥ 34 U/mL
Univariate Multivariate
OR (95% CI) p-Value OR (95% CI) p-Value
Age 0.94 (0.78, 1.02) 0.118 – –
BMI 0.99 (0.79, 1.24) 0.946 – –
Past TB history 4.71 (1.18, 18.79) 0.028 2.64 (0.44, 15.72) 0.286
Cavity 0.63 (0.15, 2.66) 0.525 – –
AFB positivity 0.84 (0.16, 4.55) 0.844 – –
Extension more than half 6.87 (1.34, 35.3) 0.021 2.75 (0.37, 20.51) 0.323
M. abscessus complex 10.13 (2.26, 45.35) 0.002 9.97 (1.58, 62.79) 0.014
Active phase of PNTM disease 16.67 (1.97, 141.24) 0.010 12.18 (1.07, 138.36) 0.044
BMI: body mass index, TB: tuberculosis, AFB: acid fast bacilli, M. abscessus complex: Mycobacterium. M. abscessus complex includes M. abscessus
c
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t
rand M. massiliense.
Although all patients with pulmonary TB showed sputum
onversion to negative (culture positive cases) and clinical
mprovement (clinically diagnosed TB cases) after anti-TB
reatment, patients with PNTM diseases were divided into
espondents (n = 17) and non-respondents (n = 7) based onthe response to anti-NTM treatment. Although the respon-
dents showed sputum culture conversion and radiologic
improvement after anti-NTM treatment within 12 months,
the non-respondents had persistent positive sputum culture
and aggravated radiologic manifestation despite anti-NTM
30  b r a z j i n f e c t d i s . 2 0 1 6;2  0(1):26–32
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Fig. 2 – Trend of CA 19-9 levels before and after treatment in patients with pulmonary nontuberculous mycobacterial (PNTM)
disease (a) and patients with active TB (b). NTM, nontuberculous mycobacterial; TB, tuberculosis. Respondents: patients who
had sputum culture conversion and radiologic improvement after anti-NTM treatment within 12 months, non-respondents:
gravpatients who  had persistent positive sputum culture and ag
treatment. The TB patients were classiﬁed into the low-risk
(n = 25) and moderate-/high-risk (n = 11) groups based on risk
factors for relapse.
The trend of serum CA 19-9 levels of the patients with
PNTM disease after treatment was different according to the
response to treatment (Fig. 2a). In the respondent group, the
serum CA 19-9 level decreased signiﬁcantly from a median
of 18.50 U/mL (IQR, 3.35–75.75) before treatment to 14.20 U/mL
(IQR, 3.90–22.10) after treatment (p = 0.004). In comparison, the
change in serum CA 19-9 levels before and after treatment
in the non-respondents group was not signiﬁcant (Pre-Tx:
7.80 U/mL; IQR, 6.10–46.10; Post-Tx: 9.70 U/mL, IQR, 5.10–42.60;
p = 0.446).
Interestingly, the trend in serum CA-19-9 levels of the
patients with pulmonary TB was different from those of the
PNTM patients (Fig. 2b). The levels of serum CA 19-9 were
not signiﬁcantly different between the low-risk and moderate-
/high-risk groups either before or after anti-TB treatment.
Additionally, the serum CA 19-9 levels before and after anti-
TB therapy were not signiﬁcantly affected by the risk factors
of relapse.
DiscussionCA 19-9 is a glycosphingolipid of the Lewis group that is well
known as a tumor-associated antigen.8 It is a useful marker
of epithelial gastrointestinal cancers and pancreatic cancer.ated radiologic manifestation despite anti-NTM treatment.
Recently, increased concentrations of serum CA 19-9 have
been reported in various non-malignant lung diseases includ-
ing bronchiectasis and emphysema.12 In particular, there
are some reports of increased CA 19-9 levels in NTM lung
disease.16,17 Our study is the ﬁrst to evaluate the clinical mean-
ing of elevated CA 19-9 in patients with PNTM disease.
CA 19-9 is synthesized and secreted by normal central air-
way and respiratory glands.23 Additionally, serum CA 19-9 is
elevated by the extravasation of mucus glycoprotein that is
hypersecreted from hypertrophic gland and epithelial cells in
bronchioles.13,16,24
In our study, we showed the signiﬁcant difference in CA
19-9 levels between patients with PNTM disease and patients
with pulmonary TB. Whereas 18.6% of the patients with PNTM
disease showed elevated serum 19-9, none of the patients with
pulmonary TB did.
The reason why CA 19-9 is higher in patients with PNTM
disease than in patients with pulmonary TB may be that
chronic inﬂammation accompanying the bronchiectasis
is more  common in patients with PNTM disease than in
those with pulmonary TB. Similarly, Kim et al. suggest
that the mechanism responsible for increased CA 19-9 in
benign pulmonary disease could be an inﬂammatory pro-
cess in bronchiectasis, bronchiolitis, interstitial ﬁbrosis, and
12emphysema. There are limitations to the use of CA 19-9
as a PNTM disease-speciﬁc marker, considering that CA 19-9
concentrations can also be increased in patients with other
benign lung diseases. Therefore, the CA 19-9 levels might be
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nterpreted by the degree of the inﬂammatory activity, not by
he etiologic agent.
In practice, it is important to interpret the clinical meaning
f the elevated CA 19-9 in patients with PNTM disease without
ancer. In our study, the level of CA 19-9 was higher in patients
ith active phase of PNTM disease and those with M. abscessus
nfection.
The initial CA 19-9 level could be the marker reﬂecting
nﬂammatory activity and guide the initiation of therapy in
NTM disease, although it is not a PNTM disease-speciﬁc
arker.
Furthermore, the CA 19-9 might be a useful tool for mon-
toring treatment response in PNTM disease. Our data show
hat a decrease in CA 19-9 levels after anti-NTM treatment
ay reﬂect culture conversion and radiological improvement.
n the other hand, the levels of CA 19-9 did not decrease
n patients with pulmonary TB, regardless of risk factors for
elapse, although all patients were cured.
This result is consistent with those of previous studies.
amazaki et al. showed that CA 19-9 was a marker for the
eterioration of a MAC infection in association with BMI and
RP.15 Tasci et al. showed that CA 19-9 does not change signif-
cantly after treatment in the patients with pulmonary TB in
ontrast with CA 125 and CA 15-3.18 Watanabe et al. found that
A 19-9 and immunoglobulin A (IgA) are signiﬁcantly higher in
atients with MAC infection than in patients with pulmonary
B and explained that these results might suggest that MAC
nfection leads to impaired airway defense.25
Although the level of serum CA-125 reﬂects the activity
nd severity in both pulmonary TB and PNTM disease,26,27
ur data suggest that CA 19-9 is useful as a marker in the
etting of PNTM disease but not in pulmonary TB. It is not
lear whether this result may originate from the difference of
nﬂammatory pathogenesis between TB and PNTM disease.
he clinical signiﬁcance of each tumor marker vis-à-vis a
peciﬁc benign disease has yet to be deﬁned, although the rel-
vance between several tumor markers and inﬂammation are
nown.28 Because the trend of CA 19-9 according to clinical
ourse was analyzed in a small number of patients, further
tudies in a larger cohort study involving PNTM diseases are
eeded.
The discrepancy of CA 19-9 levels among patients infected
ith different species in PNTM disease has not been investi-
ated. M.  abscessus infection constituted a signiﬁcant factor
ssociated with the elevation of serum CA 19-9 in PNTM
isease in our study. However, we  have not assessed the
ssociation between M.  abscessus infection and CA19-9 levels.
here is substantial overlap in the radiographic patterns of M.
bscessus infection and the nodular bronchiectatic form of M.
vium-intracellulare (MAC)  infection, although thin-walled cav-
ty and volume loss are found more  frequently in the setting of
AC infection.19,29 Therefore, there may be other mechanisms
eyond the bronchiectasis-related inﬂammatory process that
ediate inﬂammation.
This study has several limitations. First, no healthy con-
rol group was evaluated. The study was designed to evaluate
actors related to elevated CA 19-9 levels and changes in CA
9-9 level after treatment of PNTM disease and pulmonary TB.
herefore, we  measured CA 19-9 levels in patients with PNTM
isease and patients with pulmonary TB, without a control 1 6;2  0(1):26–32 31
group. Secondly, only 24 of 59 patients with PNTM disease
underwent treatment and serial blood sampling. This was
because the diagnosis is not connected to the treatment in
PNTM disease in contrast to pulmonary TB. Finally, the num-
ber of participants with PNTM and TB was small.
In conclusion, serum CA 19-9 levels were higher in patients
with PNTM disease than in TB patients. CA 19-9 elevation
was associated with active phase and M. abscessus infection
in PNTM disease. In addition, the CA 19-9 levels showed a
tendency to decrease during successful treatment of PNTM
disease unlike pulmonary TB. Therefore, CA 19-9 may be use-
ful in the evaluation of activity and therapeutic responses in
patients with PNTM disease, although it is not a PNTM disease-
speciﬁc marker.
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